Efavirenz adverse reactions

Revision as of 05:23, 2 January 2014 by Ahmed Zaghw (talk | contribs)
Jump to navigation Jump to search
Efavirenz
SUSTIVA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

ADVERSE REACTIONS

The most significant adverse reactions observed in patients treated with SUSTIVA are:

  • Psychiatric symptoms
  • Nervous system symptoms
  • Rash

The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.

References

Adapted from the FDA Package Insert.